Niagen Bioscience/$NAGE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Niagen Bioscience
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
Ticker
$NAGE
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
104
ISIN
US1710774076
Website
NAGE Metrics
BasicAdvanced
$908M
64.26
$0.18
2.08
-
Price and volume
Market cap
$908M
Beta
2.08
52-week high
$14.69
52-week low
$2.53
Average daily volume
1M
Financial strength
Current ratio
3.658
Quick ratio
3.043
Long term debt to equity
4.654
Total debt to equity
6.367
Profitability
EBITDA (TTM)
14.022
Gross margin (TTM)
62.51%
Net profit margin (TTM)
13.07%
Operating margin (TTM)
12.26%
Effective tax rate (TTM)
3.24%
Revenue per employee (TTM)
$1,040,000
Management effectiveness
Return on assets (TTM)
12.21%
Return on equity (TTM)
33.47%
Valuation
Price to earnings (TTM)
64.257
Price to revenue (TTM)
8.159
Price to book
16.33
Price to tangible book (TTM)
16.43
Price to free cash flow (TTM)
45.06
Free cash flow yield (TTM)
2.22%
Free cash flow per share (TTM)
25.52%
Growth
Revenue change (TTM)
29.77%
Earnings per share change (TTM)
-427.85%
3-year revenue growth (CAGR)
15.51%
10-year revenue growth (CAGR)
19.95%
3-year earnings per share growth (CAGR)
-23.70%
10-year earnings per share growth (CAGR)
3.28%
What the Analysts think about NAGE
Analyst ratings (Buy, Hold, Sell) for Niagen Bioscience stock.
Bulls say / Bears say
Niagen Bioscience reported a 38% year-over-year increase in net sales for Q1 2025, reaching $30.5 million, driven by strong growth in both Tru Niagen® and Niagen® ingredient sales. (niagenbioscience.com)
The company achieved a gross margin of 63.4% in Q1 2025, an improvement of 270 basis points from the prior year, indicating enhanced operational efficiency. (niagenbioscience.com)
Niagen Bioscience expanded its pharmaceutical-grade Niagen® IV therapy to nearly 600 clinics nationwide, demonstrating significant market penetration and potential for future revenue growth. (stocktitan.net)
Despite strong revenue growth, operating expenses increased by 3% in Q1 2025, which could impact future profitability if not managed effectively. (niagenbioscience.com)
The company's rebranding from ChromaDex to Niagen Bioscience may lead to temporary market confusion and require additional marketing expenditures to establish brand recognition. (investing.com)
While Niagen Bioscience has raised its full-year 2025 revenue growth outlook to 20-25%, achieving this target may be challenging amid competitive pressures in the NAD+ supplement market. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.
NAGE Financial Performance
Revenues and expenses
NAGE Earnings Performance
Company profitability
NAGE News
AllArticlesVideos
Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York
Business Wire·3 days ago
Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway
Business Wire·1 week ago
Niagen Bioscience to Participate at the Roth 15th Annual London Conference
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Niagen Bioscience stock?
Niagen Bioscience (NAGE) has a market cap of $908M as of July 17, 2025.
What is the P/E ratio for Niagen Bioscience stock?
The price to earnings (P/E) ratio for Niagen Bioscience (NAGE) stock is 64.26 as of July 17, 2025.
Does Niagen Bioscience stock pay dividends?
No, Niagen Bioscience (NAGE) stock does not pay dividends to its shareholders as of July 17, 2025.
When is the next Niagen Bioscience dividend payment date?
Niagen Bioscience (NAGE) stock does not pay dividends to its shareholders.
What is the beta indicator for Niagen Bioscience?
Niagen Bioscience (NAGE) has a beta rating of 2.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.